LUPIN PHARMACEUTICALS INC for LUPIN PHARMACEUTICALS INC
What was lobbied
7 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Lobbied for changes made to the IP chapter and agreed to in the USMCA. I follow trade agreements in general.
Foreign entity interest: Lupin Pharmaceutical Inc. (LPI) is the US subsidiary of Lupin Limited based in Mumbai, India. LPI has its commercial headquarters in Baltimore, Maryland and corporate headquarters in Naples, Florida. LPI is primarily a generic pharmaceutical manufacturer. LPI's interest is in encouraging the growth of a robust and competitive pharmaceutical market.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHAWN BROWN | Vice President of Government Affairs |
Manufacturing MAN
Any issues affecting manufacturers might affect Lupin, so I track such legislation and lobbied for inclusion of incentives for domestic manufacturing of generic medicines.
Foreign entity interest: Lupin Pharmaceutical Inc. (LPI) is the US subsidiary of Lupin Limited based in Mumbai, India. LPI has its commercial headquarters in Baltimore, Maryland and corporate headquarters in Naples, Florida. LPI is primarily a generic pharmaceutical manufacturer. LPI's interest is in encouraging the growth of a robust and competitive pharmaceutical market.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHAWN BROWN | Vice President of Government Affairs |
Disaster Planning/Emergencies DIS
None.
Foreign entity interest: Lupin Pharmaceuticals Inc. (LPI) is the US subsidiary of Lupin Ltd. based in Mumbai, India. LPI maintains a sales headquarters in Baltimore Maryland, and national headquarters in Naples, Florida. Lupin supports about 700 jobs across 4 states.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHAWN BROWN | VP of Government Affairs |
Copyright/Patent/Trademark CPT
Restrictions on patent settlements. Patent thickets. Evergreening and product hopping.
Foreign entity interest: Lupin Pharmaceuticals Inc. (LPI) is the US subsidiary of Lupin Limited based in Mumbai, India. LPI has a commercial headquarters in Baltimore, Maryland, and a Corporate Headquarters in Naples, Florida. LPI is primarily a generic pharmaceutical manufacturer, providing about 700 jobs in 4 states. LPI's interest is in encouraging the growth of a robust and competitive pharmaceutical market in the US.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHAWN BROWN | Vice President of Government Affairs |
Health Issues HCR
BLOCKING Act, Medicaid and Medicare issues, biosimilars, trade agreements, and generally any legislation affecting pharmaceutical manufacturers.
Foreign entity interest: Lupin Pharmaceutical Inc. (LPI) is the US subsidiary of Lupin Limited based in Mumbai, India. LPI has its commercial headquarters in Baltimore, Maryland and corporate headquarters in Naples, Florida. LPI is primarily a generic pharmaceutical manufacturer. LPI's interest is in encouraging the growth of a robust and competitive pharmaceutical market.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHAWN BROWN | Vice President of Government Affairs |
Medicare/Medicaid MMM
Tiering of generic medicines within Medicare. Medicaid generics penalty--inflation rebates.
Foreign entity interest: Lupin Pharmaceutical Inc. (LPI) is the US subsidiary of Lupin Limited based in Mumbai, India. LPI has its commercial headquarters in Baltimore, Maryland and corporate headquarters in Naples, Florida. LPI is primarily a generic pharmaceutical manufacturer. LPI's interest is in encouraging the growth of a robust and competitive pharmaceutical market.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHAWN BROWN | Vice President of Government Affairs |
Pharmacy PHA
None
Foreign entity interest: Lupin Pharmaceutical Inc. (LPI) is the US subsidiary of Lupin Limited based in Mumbai, India. LPI has its commercial headquarters in Baltimore, Maryland and corporate headquarters in Naples, Florida. LPI is primarily a generic pharmaceutical manufacturer. LPI's interest is in encouraging the growth of a robust and competitive pharmaceutical market.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHAWN BROWN | Vice President of Government Affairs |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| LUPIN LTD. | India | India | 3.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.